OBJECTIVE: @entity3027 signaling is regarded as a central pathogenic pathway in @entity1252 ( @entity1252 ). Specific inhibition of this pathway is a core area for the development of new therapies for @entity1252 . This study was undertaken to clarify the pathogenic mechanism involved and to identify new therapeutic targets, using a high-throughput screening platform to determine novel regulators that contribute to the overactivation of the type I @entity3027 signaling pathway in @entity1252 . METHODS: A high-throughput @entity3027 -stimulated response element (ISRE)-luciferase assay was used to screen for candidate genes that regulate the @entity3027 signaling pathway. Western blotting was used to confirm the regulatory function of @entity10610 . SYBR Green quantitative reverse transcriptase-polymerase chain reaction was used to detect the expression of individual @entity3027 -stimulated genes (ISGs). The differential expression of @entity10610 and ISGs in @entity1252 @entity1 and healthy controls was analyzed using RNA sequencing data and a microarray. RESULTS: The high-throughput ISRE-luciferase assay revealed that @entity10610 enhanced type I @entity3027 signaling. Consistent with this finding, @entity10610 promoted the type I @entity3027 -induced phosphorylation of @entity6897 and the up-regulated expression of ISGs. @entity10610 expression was elevated in peripheral blood mononuclear cells (PBMCs) and kidney biopsy specimens from @entity1252 @entity1 and correlated positively with their @entity3027 scores. A @entity10610 inhibitor reduced the expression of ISGs in PBMCs from @entity1252 @entity1 and in renal cells from @entity19 with lupus. CONCLUSION: Our findings indicate that @entity10610 is a positive regulator of the @entity3027 signaling pathway. The overexpression of @entity10610 might contribute to the abnormally amplified type I @entity3027 signaling in @entity1252 , and the inhibition of @entity10610 could be used to down-regulate type I @entity3027 signaling in @entity1252 .

Identification of XXXX as a Novel Regulator of Type I Interferon Signaling in @entity1252 .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity10610 :: ('983', 'Gene') :: ['CDK1'] @entity19 :: ('10090', 'Species') :: ['mice'] @entity1252 :: ('MESH:D008180', 'Disease') :: ['SLE', 'systemic lupus erythematosus'] @entity6897 :: ('6772', 'Gene') :: ['STAT-1'] @entity3027 :: ('3439', 'Gene') :: ['Type I interferon (IFN)', 'IFN']
@entity10610 :: (983,Gene) :: ['Cyclin-Dependent Kinase 1']
